Literature DB >> 29521579

Spinal ependymoma in adults: a multicenter investigation of surgical outcome and progression-free survival.

Maria Wostrack1, Florian Ringel1,2, Sven O Eicker3, Max Jägersberg4, Karl Schaller4, Johannes Kerschbaumer5, Claudius Thomé5, Ehab Shiban1, Michael Stoffel1,6, Benjamin Friedrich7, Victoria Kehl8, Peter Vajkoczy9, Bernhard Meyer1, Julia Onken9.   

Abstract

OBJECTIVE Spinal ependymomas are rare glial neoplasms. Because their incidence is low, only a few larger studies have investigated this condition. There are no clear data concerning prognosis and therapy. The aim of the study was to describe the natural history, perioperative clinical course, and local tumor control of adult patients with spinal ependymomas who were surgically treated under modern treatment standards. METHODS The authors performed a multicenter retrospective study. They identified 158 adult patients with spinal ependymomas who had received surgical treatment between January 2006 and June 2013. The authors analyzed the clinical and histological aspects of these cases to identify the predictive factors for postoperative morbidity, tumor resectability, and recurrence. RESULTS Gross-total resection (GTR) was achieved in 80% of cases. At discharge, 37% of the patients showed a neurological decline. During follow-up the majority recovered, whereas 76% showed at least preoperative status. Permanent functional deterioration remained in 2% of the patients. Transient deficits were more frequent in patients with cervically located ependymomas (p = 0.004) and in older patients (p = 0.002). Permanent deficits were independently predicted only by older age (p = 0.026). Tumor progression was observed in 15 cases. The 5-year progression-free survival (PFS) rate was 80%, and GTR (p = 0.037), WHO grade II (p = 0.009), and low Ki-67 index (p = 0.005) were independent prognostic factors for PFS. Adjuvant radiation therapy was performed in 15 cases. No statistically relevant effects of radiation therapy were observed among patients with incompletely resected ependymomas (p = 0.079). CONCLUSIONS Due to its beneficial value for PFS, GTR is important in the treatment of spinal ependymoma. Gross-total resection is feasible in the majority of cases, with acceptable rates of permanent deficits. Also, Ki-67 appears to be an important prognostic factor and should be included in a grading scheme for spinal ependymomas.

Entities:  

Keywords:  EOR = extent of resection; GTR = gross-total resection; PFS = progression-free survival; PR = partial resection; RT = radiation therapy; STR = subtotal resection; ependymoma; local; neoplasms; oncology; recurrence; spinal cord; spinal intradural tumor

Mesh:

Substances:

Year:  2018        PMID: 29521579     DOI: 10.3171/2017.9.SPINE17494

Source DB:  PubMed          Journal:  J Neurosurg Spine        ISSN: 1547-5646


  12 in total

1.  Clinical characteristics and surgical outcomes of ependymomas in the upper cervical spinal cord: a single-center experience of 155 consecutive patients.

Authors:  Xiaobin Fei; Wenqing Jia; Heng Gao; Chenlong Yang; Da Li; Zenghui Qian; Bo Han; Dejiang Wang; Yulun Xu
Journal:  Neurosurg Rev       Date:  2020-08-07       Impact factor: 3.042

2.  Multisegmental versus monosegmental intramedullary spinal cord ependymomas: perioperative neurological functions and surgical outcomes.

Authors:  Chenlong Yang; Jianjun Sun; Jingcheng Xie; Changcheng Ma; Bin Liu; Tao Wang; Xiaodong Chen; Jian Wu; Haibo Wu; Mei Zheng; Qing Chang; Jun Yang
Journal:  Neurosurg Rev       Date:  2021-05-14       Impact factor: 3.042

3.  Extramedullary tanycytic ependymoma of the lumbar spinal cord.

Authors:  Dong Ja Kim; Man-Hoon Han; SangHan Lee
Journal:  Yeungnam Univ J Med       Date:  2019-11-11

4.  Clinical and surgical management of holocervical spinal cord ependymomas.

Authors:  Kevin Mckay; Mark Attiah; Tianyi Niu; Daniel Nagasawa; Kunal Patel; Bilwaj Gaonkar; Barbara Van de Wiele; Natalie Moreland; Alexander Tucker; Pedro Churchman; Ulrich Batzdorf; Luke Macyszyn
Journal:  Surg Neurol Int       Date:  2019-11-22

5.  Sodium Fluorescein for Spinal Intradural Tumors.

Authors:  Semih Kivanc Olguner; Ali Arslan; Vedat Açık; İsmail İstemen; Mehmet Can; Yurdal Gezercan; Ali İhsan Ökten
Journal:  Front Oncol       Date:  2021-01-28       Impact factor: 6.244

6.  The role of clinical factors and immunocheckpoint molecules in the prognosis of patients with supratentorial extraventricular ependymoma: a single-center retrospective study.

Authors:  Liguo Wang; Song Han; Changxiang Yan; Yakun Yang; Zhiqiang Li; Zuocheng Yang
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-02       Impact factor: 4.553

7.  Magnetic resonance imaging indicators for neurological outcome after surgery in patients with intramedullary spinal ependymomas.

Authors:  Yongqiang Ma; Bofeng Bai; Xihai Zhao; Lixue Wang; Benqi Zhao; Yi Guo; Hongfang Yin; Xiaofei Zhang; Zhuozhao Zheng
Journal:  Medicine (Baltimore)       Date:  2022-01-28       Impact factor: 1.889

8.  Surgical outcome and prognostic factors in spinal cord ependymoma: a single-center, long-term follow-up study.

Authors:  Oliver Gembruch; Mehdi Chihi; Merle Haarmann; Ahmet Parlak; Marvin Darkwah Oppong; Laurèl Rauschenbach; Anna Michel; Ramazan Jabbarli; Yahya Ahmadipour; Ulrich Sure; Philipp Dammann; Neriman Özkan
Journal:  Ther Adv Neurol Disord       Date:  2021-11-10       Impact factor: 6.570

9.  Age at Diagnosis and Baseline Myelomalacia Sign Predict Functional Outcome After Spinal Meningioma Surgery.

Authors:  Johannes Wach; Mohammed Banat; Patrick Schuss; Erdem Güresir; Hartmut Vatter; Jasmin Scorzin
Journal:  Front Surg       Date:  2021-07-02

Review 10.  Spinal intramedullary schwannomas-report of a case and extensive review of the literature.

Authors:  V M Swiatek; K-P Stein; H B Cukaz; A Rashidi; M Skalej; C Mawrin; I E Sandalcioglu; B Neyazi
Journal:  Neurosurg Rev       Date:  2020-09-15       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.